

## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.usplo.gov

ATTORNEY DOCKET NO. FIRST NAMED INVENTOR CONFIRMATION NO. APPLICATION NO. FILING DATE 2023 P1134R2C4 10/688,132 10/17/2003 Avi J. Ashkenazi **EXAMINER** 05/22/2006 9157 7590 KAUFMAN, CLAIRE M GENENTECH, INC. 1 DNA WAY PAPER NUMBER ART UNIT SOUTH SAN FRANCISCO, CA 94080 1646

DATE MAILED: 05/22/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary			Application No. Ap		Applicant(s) ASHKENAZI ET AL.	
		10/688,132	,			
		Examiner	7	Art Unit		
_			Claire M. Kaufman		1646	
Period fo	- The MAILING DATE of this commu r Reply	nication appe	ears on the cover shee	t with the co	rrespondence a	ddress
WHIC - Exten after 3 - If NO - Failur Any re	DRTENED STATUTORY PERIOD F HEVER IS LONGER, FROM THE M sions of time may be available under the provision: SIX (6) MONTHS from the mailing date of this com- period for reply is specified above, the maximum s e to reply within the set or extended period for reply eply received by the Office later than three months d patent term adjustment. See 37 CFR 1.704(b).	MAILING DA s of 37 CFR 1.136 munication. tatutory period will y will, by statute, of	TE OF THIS COMMUS  (a). In no event, however, ma  Il apply and will expire SIX (6) It  cause the application to become	JNICATION.  By a reply be timely  MONTHS from the  BEABANDONED	y filed e mailing date of this o (35 U.S.C. § 133).	
Status						
1)🖾	Responsive to communication(s) file	ed on 17 Oc	tober 2003.			
·	•		action is non-final.			
3)[	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
	closed in accordance with the pract	ice under Ex	c parte Quayle, 1935 (	C.D. 11, 453	O.G. 213.	
Dispositio	on of Claims					
4)⊠ Claim(s) <u>65 and 67-93</u> is/are pending in the application.						
4	4a) Of the above claim(s) is/are withdrawn from consideration.					
5)	5) Claim(s) is/are allowed.					
6)[	S) Claim(s) is/are rejected.					
	Claim(s) is/are objected to.					
8)⊠	Claim(s) <u>65, 67-93</u> are subject to re	striction and	or election requireme	ent.		
Application	on Papers					
9)[] 7	The specification is objected to by the	ne Examiner.				
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.						
	Applicant may not request that any obje	ection to the d	rawing(s) be held in abe	yance. See 3	37 CFR 1.85(a).	
	Replacement drawing sheet(s) including	g the correction	on is required if the draw	ving(s) is objec	cted to. See 37 C	FR 1.121(d).
11) 🔲 🗆	The oath or declaration is objected t	o by the Exa	miner. Note the attac	hed Office A	ction or form P	TO-152.
Priority u	nder 35 U.S.C. § 119					
	Acknowledgment is made of a claim	for foreign p	oriority under 35 U.S.C	C. § 119(a)-(	d) or (f).	
, _	☐ All b)☐ Some * c)☐ None of:	dogumento	have been received			
	<ul> <li>1. Certified copies of the priority documents have been received.</li> <li>2. Certified copies of the priority documents have been received in Application No</li> </ul>					
	<ul><li>Certified copies of the priority</li><li>Copies of the certified copies</li></ul>					l Stage
	application from the Internation	•	•	, , , , , , , , , , , , , , , , , , ,	in the real of a	· Olago
* S	ee the attached detailed Office action			not received.		
			·			•
Attachment	(s)					·
	of References Cited (PTO-892)			ew Summary (P		
	of Draftsperson's Patent Drawing Review (I ation Disclosure Statement(s) (PTO-1449 or			No(s)/Mail Date of Informal Pate	ent Application (PT	O-152)
	No(s)/Mail Date		6) Other:		, ,	·

Application/Control Number: 10/688,132

Art Unit: 1646

## **DETAILED ACTION**

## Election/Restrictions

This application contains claims directed to the following patentably distinct species: treatment of the following conditions: T-cell mediated immune response, an inflammatory disease or disorder (including inflammation), autoimmune disease or disorder, graft vs. host disease, and allergy or asthma. The species are independent or distinct because each is caused by a different mechanism, involves distinct tissues or cells and consideration of disease type affects mode and manner of treatment.

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, no claims are generic.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which depend from or otherwise require all the limitations of an allowable generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

A telephone call was made to Diane Marschang on May 11, 2006, to request an oral election to the above restriction requirement, but did not result in an election being made.

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the

Application/Control Number: 10/688,132

Art Unit: 1646

inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C.103(a) of the other invention.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

## Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Claire M. Kaufman, whose telephone number is (571) 272-0873. Dr. Kaufman can generally be reached Monday, Tuesday, Thursday and Friday from 9:30AM to 2:30PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Nickol, can be reached at (571) 272-0835.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (571) 272-1600.

Official papers filed by fax should be directed to (571) 273-8300. NOTE: If applicant does submit a paper by fax, the original signed copy should be retained by the applicant or applicant's representative. NO DUPLICATE COPIES SHOULD BE SUBMITTED so as to avoid the processing of duplicate papers in the Office.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Claire M. Kaufman, Ph.D.

Patent Examiner, Art Unit 1646

May 12, 2006 Clau W by